UCB Announces Data On Cimzia® (certolizumab Pegol) For Patients With Moderate To Severe Rheumatoid Arthritis At American College Of Rheumatology 2012 Congress
Adverse events (AE) were comparable among the three groups and the most common serious AEs belonged to the system organ class infections and infestations (4.3% in 200 mg every two week group and none in 400 mg every four week or placebo groups).
*Certolizumab pegol in combination with methotrexate is approved in the European Union as a maintenance regimen of 200 mg every two weeks. The certolizumab pegol dosing regimen of 400 mg every four weeks is not approved in the European Union.
Improved Long-Term Household Productivity and Increased Participation in Family, Social and Leisure Activities
Presentation Title: Long-term Benefits of 4-Weekly Certolizumab Pegol and Monotherapy on Household Productivity and Social Participation in Rheumatoid Arthritis: 5 year Results from an Open-Label Extension Study
- Monday, November 12, 2012: 9:00 AM-6:00 PM
- Location: WCC: Poster Hall (Hall B)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts